Outstanding staff achievements were on show at the annual Metro North Staff Excellence Awards.
From more than 140 nominations, judges selected winners and highly commended recipients from across the health service.
A first-of-its-kind pharmaceutical program launched across Metro North Hospital and Health Service this month will allow greater access to medications for Aboriginal and Torres Strait Islander patients visiting its facilities.
Redcliffe Hospital’s new multi-storey car park is now open and available 24 hours a day, seven days a week. Across the hospital campus there are now more than 1,100 car spaces available each day for patients, visitors, and staff.
Metro North has this morning started its #COVID19 vaccine roll-out for those in Phase 1a, giving up to 180 COVID-19 vaccines today. Not in the first group? 💉 Registered Nurse Sherree Gray from Redcliffe Hospital was delighted to be one of the first to receive her vaccine this morning and has showed us how it's done 🤗
"It's very exciting to be one of the first, I feel very lucky," she said.
This makes me so happy, thank you for helping to protect us, care for us, over the last 12 months. Frontline healthcare workers are all heroes 👍
I’m a causal nurse in metro north how will I know it’s my turn and how do I sign up ? Is there list I need to get on ?
Wooooo! Sherree Ann Gray
Goooo girl! Sherree 🤩🤩🤩
The ten points of the Nuremberg Code:
(You really don't need to know much more than #1)
The ten points of the code were given in the section of the verdict entitled "Permissible Medical Experiments":
1)The voluntary consent of the human subject is absolutely essential.
2)The experiment should be such as to yield fruitful results for the good of society, unprocurable by other methods or means of study, and not random and unnecessary in nature.
3) The experiment should be so designed and based on the results of animal experimentation and a knowledge of the natural history of the disease or other problem under study that the anticipated results will justify the performance of the experiment.
4) The experiment should be so conducted as to avoid all unnecessary physical and mental suffering and injury.
5) No experiment should be conducted where there is an a prior reason to believe that death or disabling injury will occur; except, perhaps, in those experiments where the experimental physicians also serve as subjects.
6) The degree of risk to be taken should never exceed that determined by the humanitarian importance of the problem to be solved by the experiment.
7) Proper preparations should be made and adequate facilities provided to protect the experimental subject against even remote possibilities of injury, disability, or death.
😎 The experiment should be conducted only by scientifically qualified persons. The highest degree of skill and care should be required through all stages of the experiment of those who conduct or engage in the experiment.
9) During the course of the experiment the human subject should be at liberty to bring the experiment to an end if he has reached the physical or mental state where continuation of the experiment seems to him to be impossible.
10) During the course of the experiment the scientist in charge must be prepared to terminate the experiment at any stage, if he has probable cause to believe, in the exercise of the good faith, superior skill and careful judgment required of him that a continuation of the experiment is likely to result in injury, disability, or death to the experimental subject.
AstraZeneca: Corporate Rap Sheet
London-based pharmaceutical giant AstraZeneca is the result of the 1999 merger of Britain’s Zeneca, a spinoff of the old Imperial Chemical Industries specializing in cancer medications, and Sweden’s Astra AB, which was best known for the ulcer and heartburn medication Prilosec. Since that deal, the combined company has been embroiled in numerous controversies over illegal marketing, product safety, anticompetitive behavior and tax avoidance.
Advertising and Marketing Controversies
In 2003 federal officials announced that AstraZeneca had pleaded guilty to criminal and civil charges relating to the illegal marketing of the prostate cancer drug Zoladex. The company agreed to pay $355 million, consisting of $64 million in criminal fines, a $266 million settlement of civil False Claims Act charges, and a $25 million settlement of fraud charges relating to state Medicaid programs. AstraZeneca, which agreed to enter into a corporate integrity agreement with the Inspector General of the U.S. Department of Health and Human Services, had been accused of giving illegal financial inducements such as grants and honoraria to physicians.
In 2004 a coalition of consumer groups filed suit against AstraZeneca in a California state court, arguing that advertising for the company’s acid reflux drug Nexium misled consumers into thinking that it was superior to AstraZeneca’s Prilosec. The company had introduced Nexium to replace Prilosec as the latter drug was losing its patent protection. The case, along with a related one filed in Massachusetts, is pending.
Also in 2004, the U.S. Food and Drug Administration (FDA) found that AstraZeneca’s full-page newspaper advertisements defending the safety of its Crestor cholesterol medication were “false and misleading.” The warning letter sent by the agency to AstraZeneca took issue not only with what the company said about the drug but also the way it represented the FDA’s position on Crestor.
In 2010 the U.S. Justice Department announced that AstraZeneca would pay $520 million to resolve allegations that it illegally marketed its anti-psychotic drug Seroquel for uses not approved as safe and effective by the FDA. Under the terms of the settlement, $302 million of the total was to go to the federal government and $218 million to state Medicaid programs. Among other things, the company was accused of having paid doctors to give speeches and publish articles (ghostwritten by the company) promoting those unapproved uses. AstraZeneca agreed to sign a corporate integrity agreement regarding its future behavior. In 2011 AstraZeneca settled a related Seroquel case brought by state governments by agreeing to pay another $69 million.
In 2002 AstraZeneca said it would put a more conspicuous warning label on its lung cancer drug Iressa after several patients in Japan suffered pneumonia and some died.
In 2003 researchers at the University of Illinois-Chicago released the results of research concluding that AstraZeneca’s Seroquel and two other schizophrenia drugs made by other companies created an elevated risk for diabetes. Subsequently, more than 25,000 lawsuits were filed against the company. In 2010 the company said it would pay a total of $198 million to settle those cases. That same year, the UK’s Prescription Medicines Code of Practice Authority found that AstraZeneca had failed to adequately describe the risks of Seroquel in an advertisement for the drug in a medical journal.
In 2004 the watchdog group Public Citizen urged the federal government to ban AstraZeneca’s new cholesterol drug Crestor because of evidence linking it to the life-threatening muscle condition rhabdomyolysis. Noting that the company had not submitted timely reports to the FDA on some two dozen serious adverse reactions to Crestor, Public Citizen also called for a criminal investigation of the company. A 2005 study performed at Tufts University found that Crestor users had more serious side effects than those taking other cholesterol drugs.
Also in 2004, an FDA review of AstraZeneca’s new blood thinner Exanta questioned the safety and effectiveness of the drug.
Pfizer has faced thousands of lawsuits filed for medical injuries caused by some of its most popular drugs. It has also set a record for the largest fine paid for a health care fraud lawsuit filed by the U.S. Department of Justice. Pfizer paid $2.3 billion in fines, penalties, and settlement for illegal marketing claims.
Some of the Pfizer lawsuits have been dismissed, others have been settled, and still others remain in court systems. Some of the most notable lawsuits have included:
As part of a larger group of proton pump inhibitor lawsuits, Pfizer faced a number of Protonix lawsuits after it acquired drug company Wyeth who had been accused of marketing the drug for unapproved uses. In 2013, Pfizer agreed to pay $55 million to settle illegal marketing claims but the company may still be facing lawsuits for kidney injuries caused by the medication.
Nearly 10,000 Prempro lawsuits were filed by women who had been diagnosed with breast cancer. The lawsuits were largely settled by 2012 for about $1 billion.
Pfizer faced about 3,000 Chantix lawsuits filed by people who claimed they experienced suicidal thoughts and psychiatric disorders after using Chantix for smoking cessation. Pfizer set aside about $288 million and at least some of the cases were settled.
Thousands of cases of medical injury due to testosterone replacement therapy have been filed. Other drug companies have paid $ billions to settle their cases, however some Pfizer testosterone lawsuits were dismissed.
About 250 Zoloft lawsuits were filed, claiming Pfizer actively promoted the use of Zoloft to pregnant women despite knowledge of birth defect risks from their research. These cases were largely dismissed in 2016 when a judge concluded that there was not enough evidence to prove a link between birth defects and Zoloft use.
Effexor was a medication originally produced by Wyeth which has also been the cause of multiple lawsuits. People who filed Effexor lawsuits claimed that it caused birth defects, and separately, suicidal thoughts and behaviors. In September 2015, Effexor lawsuits were dismissed but may have been eligible to refile.